An update on amine oxidase inhibitors: Multifaceted drugs

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 44, Issue , 2013, Pages 118-124

  Song, Mee Sook ^a   Matveychuk, Dmitriy ^a   MacKenzie, Erin M ^a   Duchcherer, Maryana ^a   Mousseau, Darrell D ^b   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

L Deprenyl; Monoamine oxidase; Phenelzine; Primary amine oxidase; Rasagiline; Tranylcypromine

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALIPHATIC PROPARGYLAMINE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BETA PHENYLETHYLIDENEHYDRAZINE; CLORGYLINE; DRUG METABOLITE; HYDRAZINE DERIVATIVE; LADOSTIGIL; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; OMIGAPIL; PHENELZINE; PROPARGYLAMINE DERIVATIVE; RASAGILINE; SELEGILINE; TRANYLCYPROMINE; TYRAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANOXIA; APOPTOSIS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; BULIMIA; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; COCAINE DEPENDENCE; DEGENERATIVE DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG METABOLISM; DRUG OVERDOSE; ENZYME INHIBITION; FOOD; FOOD DRUG INTERACTION; GILLES DE LA TOURETTE SYNDROME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENTAL DISEASE; METHAMPHETAMINE DEPENDENCE; NARCOLEPSY; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PAIN; PANIC; PARKINSON DISEASE; POSTTRAUMATIC STRESS DISORDER; REVIEW; SOCIAL PHOBIA; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ANIMALS; DEPRESSION; HUMANS; MENTAL DISORDERS; MONOAMINE OXIDASE INHIBITORS; NERVOUS SYSTEM DISEASES;

EID: 84874767623     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.02.001     Document Type: Review

References (127)

1. Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M.B., Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002, 326:105-108.
2. Bacher I., Houle S., Xu X., Zawertailo L., Soliman A., Wilson A.A., et al. Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry 2011, 68:817-826.
3. Baker G.B., Coutts R.T., Greenshaw A.J. Neurochemical and metabolic aspects of antidepressants: an overview. J Psychiatry Neurosci 2000, 25:481-496.
4. Baker G.B., Sowa B., Todd K.G. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?. J Psychiatry Neurosci 2007, 32:313-315.
5. Baker G.B., Wong J.T., Yeung J.M., Coutts R.T. Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord 1991, 21:207-211.
6. Balu D.T., Hoshaw B.A., Malberg J.E., Rosenzweig-Lipson S., Schechter L.E., Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 2008, 1211:37-43.
7. Bar-Am O., Amit T., Youdim M.B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004, 355:169-172.
8. Bar-Am O., Amit T., Youdim M.B. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem 2007, 103:500-508.
9. Bar-Am O., Weinreb O., Amit T., Youdim M.B. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci 2009, 37:135-145.
10. Bar-Am O., Weinreb O., Amit T., Youdim M.B. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem 2010, 112:1131-1137.
11. Berry M.D. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev Recent Clin Trials 2007, 2:3-19.
12. Berry M.D., Boulton A.A. Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases. Neurotoxicol Teratol 2002, 24:667-673.
13. Birks J., Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003, CD000442.
14. Blanco C., Heimberg R.G., Schneier F.R., Fresco D.M., Chen H., Turk C.L., et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010, 67:286-295.
15. Borowsky B., Adham N., Jones K.A., Raddatz R., Artymyshyn R., Ogozalek K.L., et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A 2001, 98:8966-8971.
16. Bortolato M., Chen K., Shih J.C. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 2008, 60:1527-1533.
17. Boulton A.A., Baker G.B., Dewhurst W.G., Sandler M. Neurobiology of the trace amines: analytical, physiological, pharmacological, behavioral, and clinical aspects 1984, Humana Press, Clifton, N.J.
18. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 2001, 60:1181-1188.
19. Burke W.J., Li S.W., Chung H.D., Ruggiero D.A., Kristal B.S., Johnson E.M., et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 2004, 25:101-115.
20. Carlile G.W., Chalmers-Redman R.M., Tatton N.A., Pong A., Borden K.E., Tatton W.G. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000, 57:2-12.
21. Chen K., Maley J., Yu P.H. Potential implications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J Neurochem 2006, 99:1413-1424.
22. Chiou S.H., Ku H.H., Tsai T.H., Lin H.L., Chen L.H., Chien C.S., et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br J Pharmacol 2006, 148:587-598.
23. Davidson J.R. Pharmacotherapy of social anxiety disorder: what does the evidence tell us?. J Clin Psychiatry 2006, 67(Suppl. 12):20-26.
24. DeMarco A., Dalal R.M., Pai J., Aquilina S.D., Mullapudi U., Hammel C., et al. Racemic gamma vinyl-GABA (R, S-GVG) blocks methamphetamine-triggered reinstatement of conditioned place preference. Synapse 2009, 63:87-94.
25. Dimpfel W., Hoffmann J.A. Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol 2011, 11:2.
26. Druesne-Pecollo N., Tehard B., Mallet Y., Gerber M., Norat T., Hercberg S., et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Lancet Oncol 2009, 10:173-180.
27. Duffy S., Nguyen P.V., Baker G.B. Phenylethylidenehydrazine, a novel GABA-transaminase inhibitor, reduces epileptiform activity in rat hippocampal slices. Neuroscience 2004, 126:423-432.
28. Dwivedi Y., Rizavi H.S., Pandey G.N. Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone. Neuroscience 2006, 139:1017-1029.
29. Ebadi M., Brown-Borg H., Ren J., Sharma S., Shavali S., El ReFaey H., et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 2006, 7:1513-1529.
30. Egan C.G. Differentiation of hippocampal stem cells into functional neurons: evolving our understanding of monoamine oxidase-A inhibition. Br J Pharmacol 2006, 148:563-564.
31. Eliash S., Dror V., Cohen S., Rehavi M. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res 2009, 1256:138-148.
32. Elovaara H., Kidron H., Parkash V., Nymalm Y., Bligt E., Ollikka P., et al. Identification of two imidazole binding sites and key residues for substrate specificity in human primary amine oxidase AOC3. Biochemistry 2011, 50:5507-5520.
33. Emilsson L., Saetre P., Balciuniene J., Castensson A., Cairns N., Jazin E.E. Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients. Neurosci Lett 2002, 326:56-60.
34. Frampton J.E., Plosker G.L. Selegiline transdermal system in major depressive disorder: profile report. CNS Drugs 2007, 21:521-524.
35. Galvani S., Coatrieux C., Elbaz M., Grazide M.H., Thiers J.C., Parini A., et al. Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med 2008, 45:1457-1467.
36. Gatch M.B., Taylor C.M., Flores E., Selvig M., Forster M.J. Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol 2006, 17:151-159.
37. Gerlach M., Youdim M.B., Riederer P. Pharmacology of selegiline. Neurology 1996, 47:S137-S145.
38. Gillman P.K. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol 2011, 31:66-74.
39. Gomez-Gil E., Salmeron J.M., Mas A. Phenelzine-induced fulminant hepatic failure. Ann Intern Med 1996, 124:692-693.
40. Goverdhan P., Sravanthi A., Mamatha T. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int J Alzheimers Dis 2012, 2012:974013.
41. Green A.R., Hainsworth A.H., Jackson D.M. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 2000, 39:1483-1494.
42. Gulyas B., Pavlova E., Kasa P., Gulya K., Bakota L., Varszegi S., et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography. Neurochem Int 2011, 58:60-68.
43. Gyarfas T., Knuuttila J., Lindholm P., Rantamaki T., Castren E. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell Mol Neurobiol 2010, 30:361-368.
44. Hamann K., Shi R. Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury. J Neurochem 2009, 111:1348-1356.
45. Hara M.R., Thomas B., Cascio M.B., Bae B.I., Hester L.D., Dawson V.L., et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A 2006, 103:3887-3889.
46. Hauser R.A., Lew M.F., Hurtig H.I., Ondo W.G., Wojcieszek J., Fitzer-Attas C.J. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009, 24:564-573.
47. Hill M.N., Ho W.S., Hillard C.J., Gorzalka B.B. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J Neural Transm 2008, 115:1673-1679.
48. Holt A. Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?. J Psychiatry Neurosci 2003, 28:409-414.
49. Holt A., Berry M.D., Boulton A.A. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology 2004, 25:251-266.
50. Inaba-Hasegawa K., Akao Y., Maruyama W., Naoi M. Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. J Neural Transm 2012, 119:405-414.
51. Ivanova S., Botchkina G.I., Al-Abed Y., Meistrell M., Batliwalla F., Dubinsky J.M., et al. Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. J Exp Med 1998, 188:327-340.
52. Jiang Z.J., Richardson J.S., Yu P.H. The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathol Appl Neurobiol 2008, 34:194-204.
53. Karila L., Gorelick D., Weinstein A., Noble F., Benyamina A., Coscas S., et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008, 11:425-438.
54. Kennedy S.H., Holt A., Baker G.B. Monoamine oxidase inhibitors. Kaplan and Sadock's comprehensive textbook of psychiatry 2009, 3154-3163. Lippincott Williams & Wilkins, Philadelphia. 9th ed. B.J. Sadock, V.A. Sadock, P. Ruiz (Eds.).
55. Khundakar A.A., Zetterstrom T.S. Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation. Brain Res 2006, 1106:12-20.
56. Kosten T.A., Galloway M.P., Duman R.S., Russell D.S., D'Sa C. Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 2008, 33:1545-1558.
57. Leung G., Sun W., Zheng L., Brookes S., Tully M., Shi R. Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune encephalomyelitis mouse. Neuroscience 2011, 173:150-155.
58. Lindemann L., Hoener M.C. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci 2005, 26:274-281.
59. Ling L., Urichuk L.J., Sloley B.D., Coutts R.T., Baker G.B., Shan J.J., et al. Synthesis of N-propargylphenelzine and analogues as neuroprotective agents. Bioorg Med Chem Lett 2001, 11:2715-2717.
60. London D.R., Milne M.D. Dangers of monoamine oxidase inhibitors. Br Med J 1962, 2:1752.
61. LoPachin R.M., Gavin T., Barber D.S. Type-2 alkenes mediate synaptotoxicity in neurodegenerative diseases. Neurotoxicology 2008, 29:871-882.
62. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 2001, 22:187-194.
63. Lydiard R.B., Laraia M.T., Howell E.F., Fossey M.D., Reynolds R.D., Ballenger J.C. Phenelzine treatment of panic disorder: lack of effect on pyridoxal phosphate levels. J Clin Psychopharmacol 1989, 9:428-431.
64. MacKenzie, E.M., 2009. Neurochemistry of novel neuroprotective hydrazines (PhD Thesis). University of Alberta.
65. MacKenzie E.M., Song M.S., Dursun S.M., Baker G.B. Phenelzine: an old drug that may hold clues to the development of new neuroprotective agents. Bull Clin Psychopharmacol 2010, 20:179-186.
66. Magyar K., Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004, 25:233-242.
67. Malcolm D.E., Yu P.H., Bowen R.C., O'Donovan C., Hawkes J., Hussein M. Phenelzine reduces plasma vitamin B6. J Psychiatry Neurosci 1994, 19:332-334.
68. Malorni W., Giammarioli A.M., Matarrese P., Pietrangeli P., Agostinelli E., Ciaccio A., et al. Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 1998, 426:155-159.
69. Maragos W.F., Young K.L., Altman C.S., Pocernich C.B., Drake J., Butterfield D.A., et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice. Neurochem Res 2004, 29:741-746.
70. Marchitti S.A., Deitrich R.A., Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev 2007, 59:125-150.
71. Matveychuk D., Dursun S.M., Wood P.L., Baker G.B. Reactive aldehydes and neurodegenerative disorders. Bull Clin Psychopharmacol 2011, 21:277-288.
72. McKernan D.P., Dinan T.G., Cryan J.F. "Killing the Blues": a role for cellular suicide (apoptosis) in depression and the antidepressant response?. Prog Neurobiol 2009, 88:246-263.
73. Michael-Titus A.T., Bains S., Jeetle J., Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex-a possible mechanism of neuroprotection in major depression?. Neuroscience 2000, 100:681-684.
74. Muller J.E., Koen L., Seedat S., Stein D.J. Social anxiety disorder: current treatment recommendations. CNS Drugs 2005, 19:377-391.
75. Musgrave T., Benson C., Wong G., Browne I., Tenorio G., Rauw G., et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun 2011, 25:1677-1688.
76. Musgrave T., Tenorio G., Rauw G., Baker G.B., Kerr B.J. Tissue concentration changes of amino acids and biogenic amines in the central nervous system of mice with experimental autoimmune encephalomyelitis (EAE). Neurochem Int 2011, 59:28-38.
77. Naoi M., Maruyama W., Akao Y., Yi H., Yamaoka Y. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm Suppl 2006, 67-77.
78. Naoi M., Maruyama W., Inaba-Hasegawa K., Akao Y. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection. Int Rev Neurobiol 2011, 100:85-106.
79. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995, 15:7539-7547.
80. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996, 16:2365-2372.
81. Ono K., Hasegawa K., Naiki H., Yamada M. Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro. Neurochem Int 2006, 48:275-285.
82. Ou X.M., Chen K., Shih J.C. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A 2006, 103:10923-10928.
83. Parent M.B., Master S., Kashlub S., Baker G.B. Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. Biochem Pharmacol 2002, 63:57-64.
84. Paslawski T., Knaus E., Iqbal N., Baker G.B. 2-Phenylethylidenehydrazine, a novel inhibitor of GABA transaminase. Drug Dev Res 2001, 54:35-39.
85. Peng X.Q., Li X., Gilbert J.G., Pak A.C., Ashby C.R., Brodie J.D., et al. Gamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanism. Drug Alcohol Depend 2008, 97:216-225.
86. Popov N., Matthies H. Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. J Neurochem 1969, 16:899-907.
87. Rascol O., Lozano A., Stern M., Poewe W. Milestones in Parkinson's disease therapeutics. Mov Disord 2011, 26:1072-1082.
88. Riederer P., Lachenmayer L., Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004, 11:2033-2043.
89. Rubinstein S., Malone M.A., Roberts W., Logan W.J. Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006, 16:404-415.
90. Sabelli H.C., Mosnaim A.D. Phenylethylamine hypothesis of affective behavior. Am J Psychiatry 1974, 131:695-699.
91. Salaspuro M. Acetaldehyde: a cumulative carcinogen in humans. Addiction 2009, 104:551-553.
92. Salsali M., Holt A., Baker G.B. Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol 2004, 24:63-76.
93. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
94. Seiler N. Oxidation of polyamines and brain injury. Neurochem Res 2000, 25:471-490.
95. Setshedi M., Wands J.R., Monte S.M. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 2010, 3:178-185.
96. Shi Y., Sun W., McBride J.J., Cheng J.X., Shi R. Acrolein induces myelin damage in mammalian spinal cord. J Neurochem 2011, 117:554-564.
97. Shuaib A., Kanthan R. Amplification of inhibitory mechanisms in cerebral ischemia: an alternative approach to neuronal protection. Histol Histopathol 1997, 12:185-194.
98. Shulman K.I., Fischer H.D., Herrmann N., Huo C.Y., Anderson G.M., Rochon P.A. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry 2009, 70:1681-1686.
99. Singh M., Dang T.N., Arseneault M., Ramassamy C. Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein. J Alzheimers Dis 2010, 21:741-756.
100. Smith S.E., Lambourn J., Tyrer P.J. Antipyrine elimination by patients under treatment with monoamine oxidase inhibitors. Br J Clin Pharmacol 1980, 9:21-25.
101. Song M.S., Baker G.B., Dursun S.M., Todd K.G. The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity. J Neurochem 2010, 114:1405-1413.
102. Sowa B., Todd K.G., Tanay V.A., Holt A., Baker G.B. Amine oxidase inhibitors and development of neuroprotective drugs. Curr Neuropharmacol 2004, 2:153-168.
103. Springer J.E., Azbill R.D., Mark R.J., Begley J.G., Waeg G., Mattson M.P. 4-Hydroxynonenal, a lipid peroxidation product, rapidly accumulates following traumatic spinal cord injury and inhibits glutamate uptake. J Neurochem 1997, 68:2469-2476.
104. Stewart J.W. Treating depression with atypical features. J Clin Psychiatry 2007, 68(Suppl. 3):25-29.
105. Tafazoli S., Mashregi M., O'Brien P.J. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol Appl Pharmacol 2008, 229:94-101.
106. Tanay V.A., Todd K.G., Baker G.B. Phenylethylidenehydrazine, a novel GABA-T inhibitor, rescues neurons from cerebral ischemia. Proceedings of the 23rd Congress of the Collegium Internationale Neuropsychopharmacologicum. Montreal, Canada 2002.
107. Tatton W., Chalmers-Redman R., Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003, 110:509-515.
108. Tazik S., Johnson S., Lu D., Johnson C., Youdim M.B., Stockmeier C.A., et al. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res 2009, 15:284-290.
109. Thome J., Sakai N., Shin K., Steffen C., Zhang Y.J., Impey S., et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000, 20:4030-4036.
110. Todd K.G., Banigesh A.I., Baker G.B., Coutts R.T., Shuaib A. Phenylethylidenehydrazine, a novel GABA-T inhibitor, has neuroprotective actions in transient global ischemia. J Neurochem 1999, 73(Suppl):S202B.
111. Verleye M., Steinschneider R., Bernard F.X., Gillardin J.M. Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes. Brain Res 2007, 1138:30-38.
112. Volkel W., Sicilia T., Pahler A., Gsell W., Tatschner T., Jellinger K., et al. Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. Neurochem Int 2006, 48:679-686.
113. Wang E.Y., Gao H., Salter-Cid L., Zhang J., Huang L., Podar E.M., et al. Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity. J Med Chem 2006, 49:2166-2173.
114. Wei Z., Gabriel G.G., Rui L., Cao X., Pennington P.R., Chlan-Fourney J., et al. Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex. J Alzheimers Dis 2012, 28:403-422.
115. Weinreb O., Amit T., Bar-Am O., Youdim M.B. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010, 92:330-344.
116. Weinstock M., Luques L., Bejar C., Shoham S. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression. J Neural Transm Suppl 2006, 443-446.
117. Wood P. Neurodegeneration and aldehyde load: from concept to therapeutics. Rev Psychiatry Neurosci 2006, 31:296-297.
118. Wood P.L., Khan M.A., Moskal J.R., Todd K.G., Tanay V.A., Baker G. Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res 2006, 1122:184-190.
119. Xiao H., Lv F., Xu W., Zhang L., Jing P., Cao X. Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk. Toxicology 2011, 290:286-294.
120. Yang J., Shen J. In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. Neuroscience 2005, 135:927-937.
121. Yogev-Falach M., Bar-Am O., Amit T., Weinreb O., Youdim M.B. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 2006, 20:2177-2179.
122. Youdim M.B., Amit T., Bar-Am O., Weinreb O., Yogev-Falach M. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotox Res 2006, 10:181-192.
123. Youdim M.B., Edmondson D., Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006, 7:295-309.
124. Yu P.H., Davis B.A., Boulton A.A. Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem 1992, 35:3705-3713.
125. Yu P.H., Wright S., Fan E.H., Lun Z.R., Gubisne-Harberle D. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim Biophys Acta 2003, 1647:193-199.
126. Zhang W., Davidson J.R. Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies. Expert Opin Pharmacother 2007, 8:1861-1870.
127. Zhu W., Xie W., Pan T., Jankovic J., Li J., Youdim M.B., et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 2008, 105:1970-1978.